What is CagriSema and what is it used for?

CagriSema is a treatment related to weight management. Hi-Doctor does not prescribe it today, but our licensed doctors can review your case and propose weight management alternatives with robust clinical evidence and EU regulatory approval.

Why does Hi-Doctor not prescribe CagriSema?

Our doctors only prescribe treatments with robust clinical evidence, an EU-approved indication and a reviewed safety profile. CagriSema is not on that list today — it may be investigational, not approved, or outside the scope of what we handle via telemedicine.

What alternatives can I consider within weight management?

Our doctors review your history and propose the most appropriate treatment among those authorised in the EU for weight management. The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health remains a €35 one-off consultation. If your case is not eligible, the applicable fee is refunded.

How would my weight management consultation work?

You fill in an online medical questionnaire (~4 min). An EU-licensed doctor reviews it and replies in less than 4 hours on average via the private chat in your account. If eligible, they issue a prescription electronic prescription valid in any EU pharmacy.

Can I get a consultation for CagriSema from Slovakia?

Yes. Hi-Doctor runs 100 % online across the EU, so if you live in Slovakia you can fill in the questionnaire and receive the medical review without travelling. The electronic prescription issued by the licensed doctor is valid in any EU pharmacy under Directive 2011/24/EU; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.

Who is a candidate for a medical weight-management programme?

Adults with BMI ≥ 30, or ≥ 27 with comorbidities (hypertension, type-2 diabetes, dyslipidaemia). The doctor reviews your history, current medication and goals before proposing any treatment. It is not a cosmetic programme.

What is the private electronic prescription and why is it valid across the EU?

The private electronic prescription (Receta Médica Privada Electrónica) is issued by a licensed doctor in Spain. It is a PDF carrying every field required by EU Directive 2011/24/EU (patient, prescriber with country of registration, active ingredient, dose), which makes it legally recognised across all 27 EU member states. In Spanish pharmacies it is dispensed from the QR; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.

How does Hi-Doctor work step by step?

1) Fill in an online medical questionnaire in about 4 minutes. 2) The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health is €35 per consultation and a skin consultation is €40. 3) An EU-licensed doctor reviews your case and, if appropriate, issues an electronic prescription. 4) Collect it at any EU pharmacy. If the review is not approved, the applicable fee is refunded in full.

How much does it cost and what does the price include?

The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; a one-off sexual-health consultation is €35 and a skin consultation — acne, rosacea, melasma, ageing skin — is €40. Each includes a licensed doctor's review and an electronic prescription if approved. If the review is not approved, the applicable fee is refunded in full. Medication is paid for separately at the pharmacy at the price it sets.

Unbranded clinical vial representing investigational CagriSema; no marketed pack exists.

CagriSema · Slovakia

CagriSema in Slovakia: what you should know.

INVESTIGATIONAL · PHASE 3CagriSema is not approved in the EU and cannot be prescribed here.

We don't prescribe it today, but our doctors can review your case and propose an equivalent weight management treatment with EU approval and clinical evidence.

Review my weight management case

€25/month (billed €25 every 28 days)Full refund if a review is not approved

IN PLAIN TERMS

What CagriSema is, and how to get treatment

CagriSema is an experimental weekly injection from Novo Nordisk that puts two different appetite hormones into a single pen. It has finished large phase 3 studies but it is not approved anywhere in the world. Novo Nordisk filed an application with the United States regulator in December 2025, and no marketing authorisation has been granted in the European Union. This means no doctor in the EU can legally prescribe it and no EU pharmacy can dispense it. Anything sold online under this name is not a licensed medicine.

CagriSema is still being studied. No medicines regulator anywhere has approved it, so it is not made for sale, no pharmacy stocks it, and no doctor in the EU can prescribe it — including us. That is the law, not a limitation of any one clinic.

Learn more about peptides at Peptidepedia.

Can I get it?

Not yet, and not from anyone in the EU. CagriSema has no marketing authorisation, so it cannot legally be prescribed or dispensed here outside a clinical trial.

Why buying it online is risky

What can I take instead?

Semaglutide is approved in the EU, has published peer-reviewed trial results, and can be prescribed today if a doctor decides it suits you.

Read about Semaglutide

What do the studies show?

Every trial behind CagriSema is listed below with its registry number, how many people took part, and whether the results are peer-reviewed or a company announcement.

Jump to the studies

Local consultation facts

Can I get CagriSema in Slovakia?

No. CagriSema is not approved and cannot be prescribed in Slovakia outside a clinical trial. This is the same EU-wide legal position that applies to every provider. Hi-Doctor can assess EU-approved weight-management options instead.

Availability

CagriSema has no EU marketing authorisation, approved pack or legitimate pharmacy stock.

Country: Slovakia
Language of service: Spanish and English
LEGAL STATUS: Investigational · cannot be prescribed
Honoured locally: PDF EU prescription for an approved treatment

How the EU prescription works where you are: For an approved alternative, the EU prescription is supplied as a PDF for use in Slovakia. It is issued only if the doctor approves treatment.

THE APPROVED ROUTE

Semaglutide: an EU-authorised option.

Semaglutide has been authorised in the EU since 6 January 2022. A licensed doctor can assess whether it is appropriate, and a prescription follows only if the doctor approves.

These are Semaglutide's own trial results. Results for CagriSema may come from a different dose, duration and patient group, so the figures should not be treated as a direct comparison.

PEER-REVIEWED PIVOTAL TRIAL

STEP 1

It copies GLP-1, a hormone the gut releases after a meal, which reduces appetite and slows how quickly the stomach empties.

−14.9%

Mean change with 2.4 mg once weekly at 68 weeks; placebo was −2.4%. Separate trial, not a direct comparison.

Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 (PMID 33567185)Start a weight-management consultation

The product is the online doctor consultation. Treatment and a prescription follow only if the doctor approves.

A once-daily semaglutide tablet authorised for type 2 diabetes. Any use in weight management is an individual medical decision and may be off-label.

Daily tablets

€25/month

You pay for any medication separately at the pharmacy you choose. Hi-Doctor does not sell medications.

WHAT IT COSTS

One plan, reviewed by a doctor.

Weight loss

ONGOING PLAN

€25/month

Billed €25 every 28 days · cancel anytime

28-day treatment cycle

For ongoing treatment and doctor-reviewed renewals.

Renewals reviewed by your doctor

Start consultation

Full refund if a review is not approved

WHAT'S INCLUDED

First consultation included
Renewals reviewed by your doctor
Ongoing care with your doctor
Cancel anytime

Full refund if a review is not approved

If a review is not approved, we refund that period's €25 fee and cancel the plan.

Read the refund terms

Note: The medication, if the doctor prescribes it, is paid separately at the pharmacy at the price it sets. Hi-Doctor does not sell medications.

VERIFIED EVIDENCE

CagriSema: evidence and regulatory guide.

WHAT IT IS

How it works

A once-weekly injection that combines two appetite-reducing hormone copies in one pen: semaglutide, which acts like the gut hormone GLP-1, and cagrilintide, which acts like amylin, a hormone released by the pancreas after eating.

GLP-1
Amylin (calcitonin/amylin receptors)

DEVELOPMENT STAGE

Phase 3, partially read out

Trial register2 registered trials

Every NCT identifier links to its ClinicalTrials.gov record. A readout is not the same as peer-reviewed publication.

Registered trials for CagriSema
TRIAL / NCT	POPULATION	PARTICIPANTS	STATUS	READOUT / COMPLETION
REDEFINE 1NCT05567796	Adults with obesity, or overweight with one or more weight-related conditions, without type 2 diabetes	3,417	Read out	2025-06-22
REDEFINE 2NCT05394519	Adults with overweight or obesity and type 2 diabetes	1,206	Read out	2025-06-22

What the studies reported

Results are grouped by source and evidence grade so journal data and manufacturer announcements cannot be confused.

Peer-reviewed

Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. doi:10.1056/NEJMoa2502081

Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. doi:10.1056/NEJMoa2502081
DOSE OR GROUP	MEAN WEIGHT CHANGE	WEEKS
Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly	−22.7% body weight	68
Semaglutide 2.4 mg weekly (comparator arm)	−16.1% body weight	68
Cagrilintide 2.4 mg weekly (comparator arm)	−11.8% body weight	68
Placebo	−2.3% body weight	68
Cagrilintide 2.4 mg + semaglutide 2.4 mg weekly (REDEFINE 2, adults with type 2 diabetes)	−13.7% body weight versus −3.4% on placebo	68

These are results from the manufacturer's own phase 3 programme in selected trial populations who also received a lifestyle programme; the combination has not been assessed by any regulator in the EU, so no independent European review of the data exists.

Sources

Last reviewed 2026-07-27

NAMED SAFETY SIGNALS

What has been reported with CagriSema.

Gastrointestinal side effects overall

Reported by 79.6% of the cagrilintide–semaglutide group in REDEFINE 1, versus 39.9% on placebo; mostly mild to moderate and temporary.

Nausea

Reported by 55% in REDEFINE 1, versus 12.6% on placebo.

Constipation

Reported by 30.7% in REDEFINE 1, versus 11.6% on placebo.

Vomiting

Reported by 26.1% in REDEFINE 1, versus 4.1% on placebo.

Stopping treatment because of side effects

6.0% stopped cagrilintide–semaglutide because of an adverse event in REDEFINE 1, versus 3.7% on placebo.

UNAPPROVED PRODUCTS ONLINE

Why buying CagriSema online is not a shortcut.

CagriSema is not manufactured for an authorised market: there is no approved pack, SmPC or legitimate pharmacy stock. Products sold online are not the approved medicine.

Check the EU common logo

A legitimate online pharmacy in the EU must display the common logo linked to its national register. The logo is a verification check; it cannot make an unapproved medicine legal.

How the EU common logo works

FREQUENTLY ASKED QUESTIONS